Prostate Cancer
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Global prostate cancer market intelligence for pharma BD, investors & analysts. Track drug development, clinical trials, and regulatory approvals.
Showing 1–3 of 3 articles
Quick answer
NovaPharmaNews Prostate Cancer hub for EMA covers 3 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC
Truqap gains US approval in PTEN-deficient metastatic prostate cancer
Pfizer's Talzenna Combo: A Game Changer in Prostate Cancer Treatment
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.